RSM logo
Laboratory Animals

Home Current issue Browse archive Alerts About the journal Feedback
 
This version was published on 1 July 2009
Lab Anim 2009;43:284-290
doi:10.1258/la.2008.008032
© 2009 Laboratory Animals Limited

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
la.2008.008032v1
43/3/284    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, X.-H.
Right arrow Articles by Liu, C.-X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Articles

Limited sampling strategy in rats to predict the inhibited activities of hepatic CYP3A

Xue-Hui Zhu 1 2, Jian-Jie Jiao 1, Cai-Li Zhang 1, Jian-Shi Lou 1  and Chang-Xiao Liu 3

1 Department of Pharmacology, Basic Medical College; 2 Department of Clinical Pharmacy, College of Pharmaceutical Science, Tianjin Medical University, Tianjin 300070, China; 3 Tianjin State Key Laboratory of Pharmacokinetics and Pharmacodynamics, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China

Corresponding author: Jian-Shi Lou, No. 22, Qixiangtai Road, Tianjin, China. Email: jianshilou{at}sina.com

The present study was undertaken in order to evaluate feasibility of a limited sampling strategy (LSS) to predict the systemic clearance of midazolam (MDZ), which is a hepatic CYP3A activity phenotyping probe. Groups of rats pretreated with or without serial doses of ketoconazole, which is a selective inhibitor on CYP3A, were used as training set. Linear regression analysis and a Jack-knife validation procedure were performed based on plasma MDZ concentrations at specific time points after sublingual vein injection of MDZ to establish the most informative LSS equations for accurately estimating the clearance of MDZ. Another group of rats in the same setting was used as the validation set to confirm the individual values of estimated clearance (Clest) that were derived from the predictive equations developed in the training set. LSS that were derived from one, two or three sampling times, namely 90 min, 60–90 min, 30–60–90 min and 30–60–120 min, gave the best correlation and acceptable errors between the values of observed clearance (Clobs) and Clest and were chosen to evaluate hepatic CYP3A activity. Our results supported the hypothesis that using limited plasma sampling is simpler than the usual method of estimating CYP3A phenotyping by predicting the systemic clearance of MDZ when the hepatic activity of CYP3A is reduced in the rat. This experimental design offers opportunities to reduce animal use in the study of drug metabolism.

Key Words: Limited sampling strategy • CYP3A • liver • midazolam • ketoconazole


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





  RSM Press eJournals Collection 2010